Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 12, 2007 - Issue 2
Submit an article Journal homepage
33
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Future pharmacotherapy in chronic bladder hypersensory conditions

Toby C Chai MD FACS University of Maryland School of Medicine, Associate Professor, Division of Urology, Baltimore, MD 21201, USA +1 410 328 3083; +1 410 328 0595; [email protected]
Pages 187-190 | Published online: 29 Jun 2007

Bibliography

  • ABRAMS P, CARDOZO L, FALL M, et al.: STANDARDISATION SUB-COMMITTEE OF THE INTERNATIONAL CONTINENCE SOCIETY: The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology (2003) 61(1):37-49.
  • ABRAMS P: Urgency: the key to defining the overactive bladder. BJU Int. (2005) 96(Suppl. 1):1-3.
  • BRUBAKER L: Urgency: the cornerstone symptom of overactive bladder. Urology (2004) 64(6 Suppl. 1):12-16.
  • NABI G, CODY JD, ELLIS G, HERBISON P, HAY-SMITH J: Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst. Rev. (2006) 18(4):CD003781.
  • GRAHAM E, CHAI TC: Dysfunction of bladder urothelium and bladder urothelial cells in interstitial cystitis. Curr. Urol. Rep. (2006) 7(6):440-446.
  • SUN Y, CHAI TC: Augmented extracellular ATP signaling in bladder urothelial cells from patients with interstitial cystitis. Am. J. Physiol. Cell Physiol. (2006) 290(1):C27-C34.
  • SUN Y, CHAI TC: Up-regulation of P2X3 receptor during stretch of bladder urothelial cells from patients with interstitial cystitis. J. Urol. (2004) 171(1):448-452.
  • SUN Y, KEAY S, DE DEYNE PG, CHAI TC: Augmented stretch activated adenosine triphosphate release from bladder uroepithelial cells in patients with interstitial cystitis. J. Urol. (2001) 166(5):1951-1956.
  • TEMPEST HV, DIXON AK, TURNER WH, ELNEIL S, SELLERS LA, FERGUSON DR: P2X and P2X receptor expression in human bladder urothelium and changes in interstitial cystitis. BJU Int. (2004) 93(9):1344-1348.
  • KEAY SK, SZEKELY Z, CONRADS TP et al.: An antiproliferative factor from interstitial cystitis patients isa frizzled 8 protein-related sialoglycopeptide. Proc. Natl. Acad. Sci. USA (2004) 101(32):11803-11808.
  • CONRADS TP, TOCCI GM, HOOD BL et al.: CKAP4/p63 is a receptor for the frizzled-8 protein-related antiproliferative factor from interstitial cystitis patients. J. Biol. Chem. (2006) 281(49):37836-37843.
  • GIANNANTONI A, DI STASI SM, CHANCELLOR MB, COSTANTINI E, PORENA M: New frontiers in intravesical therapies and drug delivery. Eur. Urol. (2006) 50(6):1183-1193.
  • TYAGI P, WU PC, CHANCELLOR M, YOSHIMURA N, HUANG L: Recent advances in intravesical drug/gene delivery. Mol. Pharm. (2006) 3(4):369-379.
  • FRASER MO, CHUANG YC, TYAGI P et al.: Intravesical liposome administration – a novel treatment for hyperactive bladder in the rat. Urology (2003) 61(3):656-663.
  • TYAGI P, BANERJEE R, BASU S, YOSHIMURA N, CHANCELLOR M, HUANG L: Intravesical antisense therapy for cystitis using TAT-peptide nucleic acid conjugates. Mol. Pharm. (2006) 3(4):398-406.
  • FURUTA A, THOMAS CA, HIGAKI M, CHANCELLOR MB, YOSHIMURA N, YAMAGUCHI O: The promise of beta 3-adrenoceptor agonists to treat the overactive bladder. Urol. Clin. North Am. (2006) 33(4):539-543.
  • TIWARI A, NARUGANAHALLI KS: Current and emerging investigational medical therapies for the treatment of overactive bladder. Expert Opin. Investig. Drugs (2006) 15(9):1017-1037.
  • THEOHARIDES TC, SANT GR: Immunomodulators for treatment of interstitial cystitis. Urology (2005) 65(4):633-638.
  • PAYNE CK, MOSBAUGH PG, FORREST JB et al.: ICOS RTX STUDY GROUP (RESINIFERATOXIN TREATMENT FOR INTERSTITIAL CYSTITIS): Intravesical resiniferatoxin for the treatment of interstitial cystitis: a randomized, double-blind, placebo controlled trial. J. Urol. (2005) 173(5):1590-1594.
  • APOSTOLIDIS A, GONZALES GE, FOWLER CJ: Effect of intravesical Resiniferatoxin (RTX) on lower urinary tract symptoms, urodynamic parameters, and quality of life of patients with urodynamic increased bladder sensation. Eur. Urol. (2006) 50(6):1299-1305.
  • KIM DK, THOMAS CA, SMITH C, CHANCELLOR MB: The case for bladder botulinum toxin application. Urol. Clin. North Am. (2006) 33(4):503-510.
  • PATEL AK, PATTERSON JM, CHAPPLE CR: Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: a critical analysis of results. Eur. Urol. (2006) 50(4):684-709.
  • APOSTOLIDIS A, DASGUPTA P, FOWLER CJ: Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur. Urol. (2006) 49(4):644-650.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.